These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

450 related articles for article (PubMed ID: 24565604)

  • 1. [Cost-per-responder analysis comparing romiplostim to rituximab in the treatment of adult primary immune thrombocytopenia in Spain].
    López MF; Mingot ME; Valcárcel D; Vicente García V; Perrin A; Campos Tapias I
    Med Clin (Barc); 2015 May; 144(9):389-96. PubMed ID: 24565604
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cost per responder associated with romiplostim and rituximab treatment for adult primary immune thrombocytopenia in France].
    Chiche L; Perrin A; Stern L; Kutikova L; Cohen-Nizard S; Lefrère F
    Transfus Clin Biol; 2014 May; 21(2):85-93. PubMed ID: 24797790
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of adding rituximab to splenectomy and romiplostim for treating steroid-resistant idiopathic thrombocytopenic purpura in adults.
    Kikuchi K; Miyakawa Y; Ikeda S; Sato Y; Takebayashi T
    BMC Health Serv Res; 2015 Jan; 15():2. PubMed ID: 25609557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Cost-effectiveness of Eltrombopag for the Treatment of Immune Thrombocytopenia in the United States.
    Tremblay G; Dolph M; Roy AN; Said Q; Forsythe A
    Clin Ther; 2020 May; 42(5):860-872.e8. PubMed ID: 32199608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of a thrombopoietin receptor agonist on use of intravenous immune globulin in patients with immune thrombocytopenia.
    Zeller MP; Heddle NM; Kelton JG; Hamilton K; Wang G; Sholapur N; Carruthers J; Hsia C; Blais N; Toltl L; Hamm C; Pearson MA; Arnold DM
    Transfusion; 2016 Jan; 56(1):73-9. PubMed ID: 26400824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The burden of immune thrombocytopenia in adults: evaluation of the thrombopoietin receptor agonist romiplostim.
    Deuson R; Danese M; Mathias SD; Schoonen M; Fryzek J
    J Med Econ; 2012; 15(5):956-76. PubMed ID: 22533524
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost per response analysis of strategies for chronic immune thrombocytopenia.
    Fust K; Parthan A; Li X; Sharma A; Zhang X; Campioni M; Lin J; Wang X; Zur R; Cetin K; Eisen M; Chandler D
    Am J Manag Care; 2018 Jul; 24(8 Spec No.):SP294-SP302. PubMed ID: 30020741
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost effectiveness of romiplostim for the treatment of chronic immune thrombocytopenia in Ireland.
    Lee D; Thornton P; Hirst A; Kutikova L; Deuson R; Brereton N
    Appl Health Econ Health Policy; 2013 Oct; 11(5):457-69. PubMed ID: 23857462
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Romiplostim in chronic immune thrombocytopenic purpura.
    Cersosimo RJ
    Clin Ther; 2009 Sep; 31(9):1887-907. PubMed ID: 19843480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative treatment-related adverse event cost burden in immune thrombocytopenic purpura.
    Donga PZ; Bilir SP; Little G; Babinchak T; Munakata J
    J Med Econ; 2017 Nov; 20(11):1200-1206. PubMed ID: 28882075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Economic evaluation of Thrombopoietin Receptor Agonists in the treatment of chronic primary immune thrombocytopenia].
    Parrondo J; Grande C; Ibáñez J; Palau J; Páramo JA; Villa G
    Farm Hosp; 2013; 37(3):182-91. PubMed ID: 23789796
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of EQ-5D scores from two phase 3 clinical trials of romiplostim in the treatment of immune thrombocytopenia (ITP).
    Sanz MA; Aledort L; Mathias SD; Wang X; Isitt JJ
    Value Health; 2011 Jan; 14(1):90-6. PubMed ID: 21211490
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A decision framework for treating chronic immune thrombocytopenia with thrombopoietin receptor agonists.
    Dolph M; Roy A; Bhor M; Hearnden J; Kwon CS; Forsythe A; Tremblay G; Briggs A
    J Comp Eff Res; 2018 Aug; 7(8):775-784. PubMed ID: 29848048
    [No Abstract]   [Full Text] [Related]  

  • 14. The treatment for primary immune thrombocytopenia with romiplostim in adult and paediatric patients: use experience at a Spanish university hospital.
    Marquínez-Alonso I; Escudero-Vilaplana V; Pernía S; Beléndez Bieler C; Fernández-Llamazares CM; Sanjurjo-Sáez M
    J Clin Pharm Ther; 2014 Aug; 39(4):376-82. PubMed ID: 24702274
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparative net cost impact of the utilization of romiplostim and intravenous immunoglobulin for the treatment of patients with immune thrombocytopenia in Québec, Canada.
    Pettigrew M; Garces K; Deuson R; Kassis J; Laroche V
    J Med Econ; 2013; 16(2):318-26. PubMed ID: 23216012
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Romiplostim in children with immune thrombocytopenia: a phase 3, randomised, double-blind, placebo-controlled study.
    Tarantino MD; Bussel JB; Blanchette VS; Despotovic J; Bennett C; Raj A; Williams B; Beam D; Morales J; Rose MJ; Carpenter N; Nie K; Eisen M
    Lancet; 2016 Jul; 388(10039):45-54. PubMed ID: 27103127
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Romiplostim in adults with newly diagnosed or persistent immune thrombocytopenia.
    Lozano ML; Godeau B; Grainger J; Matzdorff A; Rodeghiero F; Hippenmeyer J; Kuter DJ
    Expert Rev Hematol; 2020 Dec; 13(12):1319-1332. PubMed ID: 33249935
    [No Abstract]   [Full Text] [Related]  

  • 18. Treatment efficacy for adult persistent immune thrombocytopenia: a systematic review and network meta-analysis.
    Puavilai T; Thadanipon K; Rattanasiri S; Ingsathit A; McEvoy M; Attia J; Thakkinstian A
    Br J Haematol; 2020 Feb; 188(3):450-459. PubMed ID: 31423574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Romiplostim for the treatment of chronic immune or idiopathic thrombocytopenic purpura: a single technology appraisal.
    Mowatt G; Boachie C; Crowther M; Fraser C; Hernández R; Jia X; Ternent L
    Health Technol Assess; 2009 Sep; 13 Suppl 2():63-8. PubMed ID: 19804691
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of self-administration of romiplostim by patients with chronic immune thrombocytopenia compared with administration by a healthcare provider.
    Selleslag D; Bird R; Altomare I; Giagounidis A; Janssens A; Pabinger I; Pullarkat V; Wei H; Kreuzbauer G
    Eur J Haematol; 2015 Feb; 94(2):169-76. PubMed ID: 25039799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.